| Company Name: |
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
|
| Tel: |
18818260767 |
| Email: |
sales@chemegen.com |
| Products Intro: |
Product Name:Ly93
CAS:1883528-69-5
Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
|
| Product Name: | Ly93 | | Synonyms: | Ly93;SMS2-IN-Ly93;2-[(2-ethylphenyl)methoxy]-N-(pyridin-3-yl)benzamide;Ly93,Ly-93;Benzamide, 2-[(2-ethylphenyl)methoxy]-N-3-pyridinyl- | | CAS: | 1883528-69-5 | | MF: | C21H20N2O2 | | MW: | 332.4 | | EINECS: | | | Product Categories: | | | Mol File: | 1883528-69-5.mol |  |
| Boiling point | 450.6±35.0 °C(Predicted) | | density | 1.191±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 250 mg/mL (752.11 mM; Need ultrasonic) | | pka | 12.67±0.70(Predicted) | | form | Solid | | color | Off-white to light yellow |
| Biological Activity | Ly93 is a selective and orally active sphingomyelin synthase 2 (SMS2) inhibitor, with an IC50 of 91 nM[1].
Ly93 (100 mg/kg, i.g. once daily for 7 days) significantly decreases the plasma SM levels of C57BL/6J mice[1].Ly93 dose-dependently attenuates the atherosclerotic lesions in the root and the entire aorta as well as macrophage content in lesions, in apolipoprotein E gene knockout mice[1]. | | References | [1]. Li Y, et al. Discovery, synthesis and anti-atherosclerotic activities of a novel selective sphingomyelin synthase 2 inhibitor. Eur J Med Chem. 2019 Feb 1;163:864-882. |
| | Ly93 Preparation Products And Raw materials |
|